Top Markets
#1 Velas Velas +480.91%
#2 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#3 Siren Siren +107.10%
#4 Venom Venom +47.47%
#5 Gigachad Gigachad +25.21%
#6 Ontology Ontology +20.20%
#7 Scor Scor +17.10%
#8 TRIA TRIA +16.34%
#9 Dacxi Dacxi +16.27%
#10 BabyBoomToken BabyBoomToken +13.98%
Coin of the day
Velas Velas
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Kedudukan dalam Saham #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Harga Saham
$0.0416118
Modal Pasaran
$12.78M
Perubahan (1 hari)
1.72%
Perubahan (1 tahun)
-22.01%
Negara
AU
Perdagangan Noxopharm Limited (NOX)

Kategori

Healthcare
Bilangan saham terbitan bagi Noxopharm Limited (NOX)
Bilangan saham terbitan setakat December 2025: 292.24M
Menurut laporan kewangan terkini dan harga saham Noxopharm Limited, bilangan saham terbitan semasa ialah 292.24M. Pada akhir June 2024, syarikat mempunyai 292.26M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Noxopharm Limited (NOX) dari 2016 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
2026 (TTM) 292.24M -0.08%
2025 292.47M 0.07%
2024 292.26M 0.01%
2023 292.24M 0.35%
2022 291.22M 10.37%
2021 263.85M 90.70%
2020 138.36M 0.15%
2019 138.15M 16.06%
2018 119.03M 35.93%
2017 87.57M 160.94%
2016 33.56M 0.00%
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 1,422.00%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -13.12%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M -64.79%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M -34.99%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M 65.47%
AU